Petros Pharmaceuticals - PTPI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 496.93%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.67
▼ -0.03 (-4.29%)

This chart shows the closing price for PTPI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Petros Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTPI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTPI

Analyst Price Target is $4.00
▲ +496.93% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Petros Pharmaceuticals in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 496.93% upside from the last price of $0.67.

This chart shows the closing price for PTPI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Petros Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2023Maxim GroupInitiated CoverageBuy$4.00Low
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/20/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Negative

  • No negative mentions tracked during this time.

Very Positive

Petros Pharmaceuticals logo
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
Read More

Today's Range

Now: $0.67
Low: $0.67
High: $0.70

50 Day Range

MA: $1.35
Low: $0.68
High: $1.72

52 Week Range

Now: $0.67
Low: $0.64
High: $9.54

Volume

161,716 shs

Average Volume

623,190 shs

Market Capitalization

$4.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Petros Pharmaceuticals?

The following sell-side analysts have issued reports on Petros Pharmaceuticals in the last year: Maxim Group.
View the latest analyst ratings for PTPI.

What is the current price target for Petros Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Petros Pharmaceuticals in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 496.9%. Maxim Group has the highest price target set, predicting PTPI will reach $4.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $4.00 for Petros Pharmaceuticals in the next year.
View the latest price targets for PTPI.

What is the current consensus analyst rating for Petros Pharmaceuticals?

Petros Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTPI will outperform the market and that investors should add to their positions of Petros Pharmaceuticals.
View the latest ratings for PTPI.

What other companies compete with Petros Pharmaceuticals?

How do I contact Petros Pharmaceuticals' investor relations team?

Petros Pharmaceuticals' physical mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company's listed phone number is 973-242-0005 and its investor relations email address is [email protected]. The official website for Petros Pharmaceuticals is www.petrospharma.com. Learn More about contacing Petros Pharmaceuticals investor relations.